Peter Enzinger, MD, answers common questions about the diagnosis and management of esophageal cancer in this clinician-focused FAQ interview.
Peter C. Enzinger, MD, Dana-Farber Cancer Institute
Advertisement
Articles by Peter C. Enzinger, MD, Dana-Farber Cancer Institute
Peter C. Enzinger, MD, discusses the significance of Claudin 18.2 and HER2 as actionable biomarkers in gastroesophageal cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5